The Kodiak thing has my head spinning. If that happened to PYC as they entered P1 trials it could be the way the valuation change occurs. If they sell 5% (more than Kodiak did) of Visionpharma for USD200m (less than Kodiak got) then the remaining 80% would be instantly valued at USD3.2b and there could be a capital return equal to PYCs current share price (80% of USD200m = AUD230m).
that would be the best way to get the share price revalued and only give away 5% of one subsidiary.
mind blowing numbers.
The Kodiak thing has my head spinning. If that happened to PYC...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.010(0.83%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.23 | $1.19 | $1.081M | 900.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 455405 | $1.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.22 | 59014 | 1 |
View Market Depth
| Last trade - 14.57pm 24/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |